

Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Sara A. Hurvitz, Luc Dirix, Judit Kocsis, Giulia V. Bianchi, Janice Lu, Jeferson Vinholes, Ellie Guardino, Chunyan Song, Barbara Tong, Vivian Ng, Yu-Waye Chu, and Edith A. Perez

A B S T R A C T

Purpose

Trastuzumab emtansine (T-DM1), an antibody-drug conjugate composed of the cytotoxic agent DM1 conjugated to trastuzumab via a stable thioether linker, has shown clinical activity in single-arm studies enrolling patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer (MBC) whose disease had progressed on HER2-targeted therapy in the metastatic setting.

Patients and Methods

Patients (N = 137) with HER2-positive MBC or recurrent locally advanced breast cancer were randomly assigned to trastuzumab plus docetaxel (HT; n = 70) or T-DM1 (n = 67) as first-line treatment until disease progression or unacceptable toxicity. Primary end points were investigator-assessed progression-free survival (PFS) and safety. Key secondary end points included overall survival (OS), objective response rate (ORR), duration of objective response, clinical benefit rate, and quality of life.

Results

Median PFS was 9.2 months with HT and 14.2 months with T-DM1 (hazard ratio, 0.59; 95% CI, 0.36 to 0.97); median follow-up was approximately 14 months in both arms. ORR was 58.0% (95% CI, 45.5% to 69.2%) with HT and 64.2% (95% CI, 51.8% to 74.8%) with T-DM1. T-DM1 had a favorable safety profile versus HT, with fewer grade ≥ 3 adverse events (AEs; 46.4% v 90.9%), AEs leading to treatment discontinuations (7.2% v 40.9%), and serious AEs (20.3% v 25.8%). Preliminary OS results were similar between treatment arms; median follow-up was approximately 23 months in both arms.

Conclusion

In this randomized phase II study, first-line treatment with T-DM1 for patients with HER2-positive MBC provided a significant improvement in PFS, with a favorable safety profile, versus HT.

J Clin Oncol 31:1157-1163. © 2013 by American Society of Clinical Oncology

INTRODUCTION

Overexpression of human epidermal growth factor receptor 2 (HER2) occurs in approximately 20% of breast cancers^{1,2} and is associated with increased mortality in early-stage disease, decreased time to relapse, and increased incidence of metastases compared with HER2-normal breast cancer.³⁻⁵ However, patients treated with HER2-targeted therapies have improved clinical outcomes versus those treated with chemotherapy alone. In nonrandomized studies, single-agent trastuzumab has modest activity in the treatment of HER2-positive metastatic breast cancer (MBC).⁶⁻⁸ Trastuzumab plus taxane-based chemotherapy demonstrated significantly im-

proved overall survival (OS) and progression-free survival (PFS) over chemotherapy alone^{9,10} as first-line therapy for HER2-positive MBC, a finding confirmed in other trials of trastuzumab-containing regimens.¹¹ Nevertheless, MBC will eventually progress in most patients. Moreover, chemotherapy-associated toxicity is a significant source of patient morbidity.^{9,10} Severe myelosuppression is frequently observed in patients receiving docetaxel and can be a barrier to adequate treatment for MBC. Even nonserious adverse events (AEs) commonly associated with chemotherapy confer a substantial negative effect on patient quality of life (QOL).¹² Thus, there remains a need for more effective and better-tolerated therapies for HER2-positive MBC.

Sara A. Hurvitz, University of California at Los Angeles Jonsson Comprehensive Cancer Center and Translational Oncology Research International, Los Angeles, CA; Luc Dirix, Sint-Augustinus Hospital, Antwerp, Belgium; Judit Kocsis, Semmelweis University Hospital, Budapest, Hungary; Giulia V. Bianchi, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Janice Lu, State University of New York at Stony Brook, Stony Brook, NY; Jeferson Vinholes, Clinica de Oncologia, Porto Alegre, Brazil; Ellie Guardino, Chunyan Song, Barbara Tong, Vivian Ng, and Yu-Waye Chu, Genentech, South San Francisco, CA; and Edith A. Perez, Mayo Clinic, Jacksonville, FL.

Published online ahead of print at www.jco.org on February 4, 2013.

Supported by Genentech with funding for third-party writing assistance for this article.

Presented at the European Multidisciplinary Cancer Congress, Stockholm, Sweden, September 23-27, 2011, and the European Society of Medical Oncology Congress, Milan, Italy, October 8-12, 2010.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Clinical trial information: NCT00679341.

Corresponding author: Edith A. Perez, MD, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224; e-mail: perez.edith@mayo.edu.

© 2013 by American Society of Clinical Oncology

0732-183X/13/3109-1157/\$20.00

DOI: 10.1200/JCO.2012.44.9694

Trastuzumab emtansine (T-DM1)—composed of cytotoxic microtubule polymerization inhibitor DM1 conjugated to the humanized, monoclonal antibody trastuzumab via a stable thioether linker¹³—is a HER2-targeted antibody-drug conjugate (ADC) in development for the treatment of HER2-positive cancer. T-DM1 is unique among ADCs; it selectively delivers a cytotoxic agent to tumor cells, and the targeting antibody trastuzumab is itself approved to treat MBC.^{14,15}

Studies of single-agent T-DM1 at 3.6 mg/kg administered once every 3 weeks in patients previously treated with multiple therapies for HER2-positive MBC demonstrated encouraging efficacy with a tolerable safety profile.^{16–18} Investigator-reported objective response rates (ORRs) were 32.7% to 44.0%, and many of the AEs associated with systemic chemotherapies were observed at lower rates relative to historical data.

Preliminary response and tolerability data from TDM4450g [A Study of the Efficacy and Safety of Trastuzumab-MCC-DM1 vs Trastuzumab (Herceptin) and Docetaxel (Taxotere) in Patients With Metastatic HER2-Positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease] were previously presented.^{19,20} Here, we report the primary efficacy and safety results of TDM4450g—which is, to the best of our knowledge, the first direct comparison of T-DM1 with an active HER2-targeted regimen for the first-line treatment of HER2-positive MBC.

PATIENTS AND METHODS

Patients

Eligible patients were ≥ 18 years of age with histologically or cytologically confirmed, HER2-positive, unresectable, locally advanced breast cancer and/or MBC without prior chemotherapy or trastuzumab for metastatic disease. HER2-positivity was defined as immunohistochemistry 3+ ($> 10\%$ cell staining) or fluorescent in situ hybridization–positive by local laboratory testing (ratio ≥ 2.0). Other inclusion criteria included measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0,²¹ Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, and adequate organ function.

Exclusion criteria included less than 6 months from completion of cytotoxic chemotherapy in the neoadjuvant/adjuvant setting until diagnosis of MBC, trastuzumab ≤ 21 days before random assignment, untreated or symptomatic brain metastases, treatment for brain metastases ≤ 60 days before random assignment, cumulative anthracycline dose equivalent to doxorubicin more than 500 mg/m², history of significant cardiovascular or other severe uncontrolled systemic disease, and/or grade ≥ 3 peripheral neuropathy.

The protocol was approved by the institutional review boards of all participating institutions and was carried out in accordance with the Declaration of Helsinki, current US Food and Drug Administration Good Clinical Practices, and applicable local laws. Patients provided written informed consent.

Study Design

In this phase II, multicenter, open-label study, patients were randomly assigned 1:1 to either T-DM1 3.6 mg/kg intravenously (IV) once every 3 weeks or trastuzumab 8 mg/kg IV loading dose followed by 6 mg/kg once every 3 weeks and docetaxel 75 or 100 mg/m² (HT; per investigator discretion) IV once every 3 weeks. Treatment continued until progressive disease (PD) or unacceptable toxicity. Eligible patients were randomly assigned by using a hierarchical dynamic randomization algorithm to ensure balance between the treatment arms, based on world region (United States/non–United States), prior adjuvant or neoadjuvant trastuzumab therapy (yes/no), and disease-free interval (≤ 24 or > 24 months).

Selected AEs were prespecified in the protocol for dose modifications, delays, or discontinuations of T-DM1 (Appendix Table A1, online only). Although premedication was not used for the initial dose of T-DM1, premedication for docetaxel was allowed according to standard practice guidelines. Trastuzumab dose reductions were not permitted; however, its administration could be delayed to assess or treat prespecified AEs.

Patients randomly assigned to T-DM1 who discontinued T-DM1 for unacceptable DM1-related toxicities were eligible to receive single-agent trastuzumab. For patients in the HT arm, if either trastuzumab or docetaxel was discontinued before PD, the remaining agent could be continued once every 3 weeks. Patients assigned to HT treatment who discontinued treatment because of PD were eligible to cross over to T-DM1 3.6 mg/kg once every 3 weeks.

Primary end points were investigator-assessed PFS and safety. Secondary end points included OS, ORR, duration of response (DOR), clinical benefit rate (CBR), and QOL as measured by the Trial Outcome Index-Physical/Functional/Breast (TOI-PFB),^{22,23} a subset of the Functional Assessment of Cancer Therapy-Breast (FACT-B),²² a summary measurement of physical and functional well-being and breast cancer–specific symptoms.

Assessments

Tumor assessments were conducted at baseline and every 9 weeks from treatment start until PD, death, or study termination, whichever occurred first. All patients with PD were observed for survival approximately every 3 months until death, loss to follow-up, withdrawal of consent, or study termination. Tumor responses were evaluated per modified RECIST, version 1.0; the modification was defined as a minimum of a 5-mm increase in the sum of the longest diameter in determining PD and a $\geq 20\%$ increase in the sum of the longest diameter of target lesions relative to nadir. Objective response was defined as complete response (CR) or partial response on two consecutive tumor assessments ≥ 4 weeks apart. CBR was defined as a CR or partial response during the study or stable disease sustained for ≥ 6 months after random assignment.

AEs were categorized by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 3.0. Complete blood counts were assessed on days 1, 8, and 15 of cycles 1 through 3, and days 1 and 8 of every cycle thereafter. Serum chemistries were assessed on days 1 and 8 of every cycle. Cardiac echocardiogram or multigated acquisition scans were obtained at screening and every 9 weeks thereafter until PD or study termination.

Archival tumor tissue from the initial breast cancer diagnosis was collected and evaluated centrally for HER2 expression (fluorescent in situ hybridization or immunohistochemistry). Patients completed the FACT-B questionnaire on day 1 of all cycles until PD or treatment discontinuation.

Statistical Analysis

The primary efficacy analysis included all randomly assigned patients, and all efficacy and safety analyses were based on clinical data before T-DM1 crossover. PFS was defined as the time from random assignment to the first occurrence of PD or death as a result of any cause within 30 days of the last administered dose of drug. Data were censored at the last tumor assessment date before crossover (or at the date of random assignment plus 1 day, if no assessment was performed after baseline) for patients who did not experience PD or death within 30 days of the last administered dose. The hazard ratio (HR) of PFS comparing T-DM1 with HT and its 95% CIs were estimated from a Cox proportional hazards model, stratified by stratification factors used in random assignment. A stratified two-sided log-rank test measured the difference in PFS between the two arms.

All treated patients were included in the safety analyses on the basis of actual treatment received. Two patients randomly assigned to HT received a single dose of T-DM1 in error and were included in the T-DM1 group for safety analyses.

QOL analyses were performed for patients who had a FACT-B assessment at cycle 1 and at one or more cycles thereafter. The primary analysis evaluated the time to symptom deterioration in the TOI-PFB subset of FACT-B; a decrease of five or more points in the TOI-PFB was considered clinically meaningful.²³

This study had a hypothesis-generating statistical design. Genentech collected and analyzed the data; all authors had access to the primary data.

RESULTS

The data cutoff for the primary efficacy and safety analysis was November 15, 2010, after 75 PFS events were observed. An updated safety analysis was performed with a data cutoff of August 31, 2011, and is reported here.

Patient Characteristics

Between July 2008 and December 2009, 137 patients were randomly assigned to HT (n = 70) or T-DM1 (n = 67). Baseline characteristics were similar between arms (Table 1). Similar numbers of patients in the HT and T-DM1 arms had previously received treatment with anthracyclines (48.6% and 44.8%, respectively). Prior treatment with neoadjuvant or adjuvant trastuzumab (27.1% and 17.9%, respectively) or taxanes (40.0% and 32.8%, respectively) was fairly well balanced between arms. In the HT arm, most patients (74.2%) initiated docetaxel at a dose of 75 mg/m². Thirty-five patients randomly assigned to HT received T-DM1 as second-line treatment as of August 2011.

Treatment

Two patients in the HT arm did not receive treatment (because they withdrew from the trial). All patients in the T-DM1 arm received treatment (Fig 1). Median durations of follow-up were approximately 14 months for the efficacy analysis and approximately 23 months for the updated safety analyses.

Median treatment duration was 8.1 months (range, 1 to 29 months) for trastuzumab, 5.5 months (range, 0 to 22 months) for docetaxel, and 10.4 months (range, 0 to 29 months) for T-DM1; the median number of cycles was 12 (range, two to 43 cycles), eight (one to 31 cycles), and 16 (one to 41 cycles), respectively. Based on prespecified protocol guidelines (Appendix Table A1), the docetaxel dose was reduced in 23 patients (34.8%); the T-DM1 dose was reduced in 14 patients (20.3%). At the August 2011 data cutoff, three patients (4.3%) were continuing HT, four (5.7%) were continuing trastuzumab alone, and 14 (20.9%) were continuing T-DM1. The most common reason for treatment discontinuation in both arms was PD (50 [71.4%] patients in the HT arm and 42 [62.7%] patients in the T-DM1 arm).

Efficacy

In the primary efficacy analysis, T-DM1 provided significant improvement in PFS over HT, with an estimated stratified HR of 0.59 (95% CI, 0.36 to 0.97; *P* = .035). The median PFS was 9.2 months in the HT arm versus 14.2 months in the T-DM1 arm (Fig 2). Similar results were seen in patients confirmed to be HER2-positive per retrospective central testing (9.8 v 14.2 months, respectively; HR, 0.53; 95% CI, 0.29 to 0.97; *P* = .037; n = 52 in both arms). Four patients in the HT arm (one each: PD, toxicity, patient withdrew consent, and unknown) and seven patients in the T-DM1 arm (six patients with PD, one physician withdrawal) had a PFS event within the first 2 months.

The ORR in the HT arm was 58.0% (95% CI, 45.5% to 69.2%) with three CRs versus 64.2% (95% CI, 51.8% to 74.8%) with seven CRs in the T-DM1 arm (*P* = .458). Of 40 patients with an objective

Table 1. Selected Patient Demographic and Baseline Characteristics

Characteristic	HT (n = 70)		T-DM1 (n = 67)	
	No.	%	No.	%
Age, years				
Median	52.0		55.0	
Range	33-75		27-82	
World region				
North America		28.6		31.3
Central and South America		28.6		23.9
Europe		42.9		44.8
Race				
White		82.9		77.6
American Indian or Alaskan native		10.0		7.5
Black		4.3		4.5
Other or N/A		2.9		10.4
ECOG PS				
0		63.8*		65.7
1		36.2*		34.3
HER2 status by central laboratory†				
HER2-positive		85.9		85.7
Normal		14.1		14.3
ER/PR status				
ER-positive and/or PR-positive		54.3		49.3
ER-negative and PR-negative		41.4		47.8
ER and PR unknown		4.3		3.0
Stage at initial diagnosis				
I to III		68.1‡		58.2
IV		29.0‡		34.3
Unknown		2.9‡		7.5
No. of distinct sites of involvement				
1-2		49.3		35.8
> 2		50.7		64.2
Lung or liver involvement				
Yes		67.1		71.6
No		31.4		26.9
Unknown		1.4		1.5
Disease-free interval, months				
≤ 24		64.3		59.7
> 24		35.7		40.3
Prior treatment				
Trastuzumab		27.1		17.9
Taxane		40.0		32.8
Anthracycline		48.6		44.8
Total no. of prior chemotherapy agents				
Median		3		3
Range		1-4		1-6

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HT, trastuzumab plus docetaxel; N/A, not available; PR, progesterone receptor; T-DM1, trastuzumab emtansine.

*ECOG PS data were available for 69 patients in the HT arm.

†Central testing for HER2 status was available for 64 patients in the HT arm and 63 patients in the T-DM1 arm.

‡Data on stage at initial diagnosis were available for 69 patients in the HT arm.

response to HT, median DOR was 9.5 months (95% CI, 6.6 to 10.6 months; Fig 3). Of 43 patients with an objective response to T-DM1, median DOR was not reached; the twenty-fifth percentile of the DOR was 8.8 months. The CBRs were 81.2% (95% CI, 70.7% to 89.1%) and 74.6% (95% CI, 63.2% to 84.2%; *P* = .358) for HT and T-DM1, respectively.




Fig 1. CONSORT diagram. (*) Includes three patients who received at least one dose of trastuzumab alone or trastuzumab plus docetaxel. (†) Two patients mistakenly received a dose of trastuzumab emtansine (T-DM1) and were thus included in the T-DM1 group for the safety analyses. (‡) One patient was not included in the efficacy analysis as a result of study site withdrawal. DFI, disease-free interval; HER2, human epidermal growth factor receptor 2; IV, intravenous; MBC, metastatic breast cancer; PD, progressive disease.

A preliminary OS analysis was performed, with a median follow-up of approximately 23 months in both arms (Appendix Fig A1, online only). With 13 deaths reported in each arm, the stratified HR of death for T-DM1 relative to HT was 1.06 (95% CI, 0.477 to 2.352; *P* = .889).

Safety

Compared with the HT group, the T-DM1 group had fewer grade ≥ 3 AEs (90.9% v 46.4%); grade 4 AEs occurred in 57.6% and 5.8% of patients, respectively. Serious AEs (25.8% v 20.3%) and AEs leading to treatment discontinuation (40.9% v 7.2%) also occurred less frequently with T-DM1. There were no reports of symptomatic congestive heart failure. Three patients per group had decreased left ventricular ejection fractions (LVEF; HT: two grade 2 and one grade 3

event; T-DM1: two grade 1 and one grade 3 event). Two patients in the HT group had postbaseline LVEF ≤ 40% based on local assessment; both had prior anthracycline therapy in the adjuvant setting. One patient in the T-DM1 group had LVEF ≤ 40%. This patient had not received prior anthracycline treatment and did not have a cardiac medical history; no symptoms within the time frame of the LVEF decrease and no medical intervention were reported.

Among patients evaluable for safety, most AEs were grade 1 or 2 in both treatment groups. The most common AEs of any grade (Table 2) in the HT group were alopecia, neutropenia, diarrhea, and fatigue. Consistent with this, more patients in the HT group were treated with colony-stimulating factors (44.3% v 6.0% in the T-DM1 group). In the T-DM1 group, the most common AEs were fatigue, nausea, increase in serum AST, pyrexia, and headache.




Fig 2. Kaplan-Meier estimates of progression-free survival (PFS) in the overall study population. The median duration of PFS was 14.2 months in the trastuzumab emtansine (T-DM1) arm and 9.2 months in the trastuzumab plus docetaxel (HT) arm, which corresponds to a hazard ratio (HR) for progression of 0.59 (*P* = .035).




Fig 3. Kaplan-Meier estimates of duration of response (DOR) by investigator. In patients with measurable disease at baseline with an objective response, the median DOR was 9.5 months (95% CI, 6.6 to 10.6 months) in the trastuzumab plus docetaxel (HT) arm (n = 40); in the trastuzumab emtansine (T-DM1) arm (n = 43), the median DOR was not reached (NR).

Table 2. Adverse Events of Any Grade Occurring in $\geq 25\%$ and/or Grade ≥ 3 Occurring in $\geq 5\%$ of Patients in Either Treatment Group

Adverse Event	All Grade				Grade $\geq 3^*$			
	HT (n = 66)†		T-DM1 (n = 69)†‡		HT (n = 66)†		T-DM1 (n = 69)†‡	
	No.	%	No.	%	No.	%	No.	%
Hematologic								
Neutropenia§	43	65.2	11	15.9	41	62.1	4	5.8
Thrombocytopenia§	4	6.1	19	27.5	2¶	3.0	5¶	7.2
Leukopenia§	17	25.8	7	10.1	16	24.2	0	
Febrile neutropenia	9	13.6	0		9	13.6	0	
Anemia	18	27.3	9	13.0	3	4.5	2	2.9
Nonhematologic								
Alopecia	44	66.7	3	4.3	—		—	
Fatigue	30	45.5	34	49.3	3	4.5	3	4.3
Nausea	29	43.9	34	49.3	0		2	2.9
Diarrhea	30	45.5	11	15.9	2	3.0	0	
Peripheral edema	29	43.9	7	10.1	4	6.1	0	
Increased AST	4	6.1	30	43.5	0		6	8.7
Pyrexia	15	22.7	28	40.6	1	1.5	0	
Headache	12	18.2	28	40.6	0		0	
Back pain	21	31.8	19	27.5	3	4.5	1	1.4
Epistaxis	6	9.1	19	27.5	0		0	
Dyspnea	18	27.3	10	14.5	2	3.0	0	
Arthralgia	20	30.3	16	23.2	1	1.5	0	
Cough	14	21.2	18	26.1	0		0	
Vomiting	17	25.8	17	24.6	0		2	2.9
Increased ALT	4	6.1	18	26.1	0		7	10.1
Pneumonia	1	1.5	6	8.7	0		4	5.8

NOTE. Bold indicates those adverse events with $\geq 20\%$ difference in incidence between treatment groups.

Abbreviations: HT, trastuzumab plus docetaxel; MedDRA, Medical Dictionary for Regulatory Activities; T-DM1, trastuzumab emtansine.

*No adverse events listed were grade 5.

†Two patients mistakenly received a dose of T-DM1 and were thus included in the T-DM1 group for safety analyses.

‡Includes three patients who received at least one dose of trastuzumab alone or HT.

§Neutropenia includes events classified as MedDRA-preferred terms “neutropenia” or “neutrophil count decreased”; thrombocytopenia includes events classified as MedDRA-preferred terms “thrombocytopenia,” “platelet count decreased,” or “heparin-induced thrombocytopenia”; leukopenia includes events classified as MedDRA-preferred terms “leukopenia” or “white blood cell count decreased.”

¶All of these events were grade 3.

||National Cancer Institute Common Terminology Criteria for Adverse Events v.3 categorizes alopecia only as grade 1 or grade 2; there is no grade ≥ 3 for this adverse event.

As of the updated safety data cutoff date, 12 patients in the HT group and 14 patients in the T-DM1 group in the population evaluable for safety died, most commonly because of PD in both groups. Among these patients, one per group had an AE that resulted in death: one cardiopulmonary failure in the HT group and one sudden death in the T-DM1 group. Neither death was attributed to study treatment per investigator assessment.

QOL

The FACT-B completion rate was more than 90%. Mean changes from baseline in FACT-B TOI scores were more favorable in the T-DM1 arm versus the HT arm across all treatment cycles (Fig 4A). The time to a decrease of five or more points in TOI-PFB score was significantly delayed in the T-DM1 arm, from a median of 3.5 months in the HT arm to 7.5 months in the T-DM1 arm (HR, 0.58; 95% CI, 0.36 to 0.92; $P = .022$; Fig 4B).

DISCUSSION

In this study of first-line treatment for HER2-positive MBC, T-DM1 provided a clinically meaningful and statistically significant 41% reduc-

tion in the relative risk of PD versus standard treatment. Although the ORRs and CBRs were similar between the two arms, the median PFS was 9.2 months in the HT arm versus 14.2 months in the T-DM1 arm. The ORR and PFS observed in the HT arm are consistent with historical phase II data.^{10,24-27} The greater number of PFS events with T-DM1 compared with HT observed in the early part of the Kaplan-Meier PFS curves (Fig 2) could be the result of disproportionate toxicity in the T-DM1 arm, a confounding factor, the existence of HER2-normal metastases, or random chance resulting from the small number of events occurring in this early time period (13 in the HT arm and 15 in T-DM1 arm). This difference is not likely due to greater toxicity with T-DM1 since disease progression was the PFS event for nearly all patients in the T-DM1 arm (six of seven patients) with early PFS events. Disease burden was greater at study entry in the T-DM1 arm compared with the HT arm (Genentech data on file), which could have contributed to the greater number of early PFS events in the T-DM1 arm.

The improvement in PFS observed with T-DM1 in this study was associated with a more durable response, which could result from greater potency related to its unique mechanisms of action, longer treatment duration enabled by its favorable safety and tolerability, or both. Notably, grade 4 AEs were reported for 57.6% of patients




Fig 4. (A) Mean change in Functional Assessment of Cancer Therapy-Breast (FACT-B) Trial Outcome Index (TOI) scores from baseline. Data are shown through cycle 16. For later cycles, the number of patients was less than 20 for at least one treatment group. (B) Kaplan-Meier estimates of time to symptom progression (TOI-PFB [Trial Outcome Index-Physical/Functional/Breast]). In patients with baseline plus at least post-baseline score, median time to decrease of five or more points in TOI-PFB score was 3.5 months in the trastuzumab plus docetaxel (HT) arm versus 7.5 months in the trastuzumab emtansine (T-DM1) arm (hazard ratio [HR], 0.58; 95% CI, 0.36 to 0.92; $P = .022$).

receiving HT versus 5.8% of those receiving T-DM1. Furthermore, AEs leading to treatment discontinuation (of either drug) occurred in 40.9% of patients in the HT group versus 7.2% in the T-DM1 group.

Patients receiving HT experienced more all-grade alopecia, neutropenia, peripheral edema, and diarrhea than those receiving T-DM1; T-DM1 was associated with more all-grade headache and thrombocytopenia, as well as an increase in serum AST and ALT. Although the incidence of all-grade thrombocytopenia was higher for T-DM1 than HT, the incidence of grade ≥ 3 thrombocytopenia was low in both groups, and there were no grade ≥ 3 hemorrhagic events observed for T-DM1. At the updated safety data cutoff, reported deaths (primarily due to PD) were well balanced between groups (HT, $n = 12$; T-DM1, $n = 14$), and no treatment-associated deaths were observed.

The frequency and severity of cardiac dysfunction was of special interest, given its association with trastuzumab treatment.^{28,29} In this

small patient population, no clinically significant cardiac events were reported, and LVEF $\leq 40\%$ occurred in only three patients (HT, $n = 2$; T-DM1, $n = 1$).

The favorable safety profile associated with T-DM1 appears to translate into superior overall QOL. Although most studies fail to demonstrate an appreciable difference in QOL between standard of care and experimental agents,³⁰⁻³² T-DM1 demonstrated a statistically and clinically meaningful difference in TOI-PFB score versus HT.

In this phase II study, T-DM1 was superior to first-line HT therapy in terms of PFS, safety, and QOL. To the best of our knowledge, this is the first randomized study to evaluate an ADC for HER2-positive MBC, and these results demonstrate the therapeutic potential of the ADC platform to improve benefit and decrease risk in this population. This was also demonstrated in EMILIA, the first randomized phase III study of T-DM1 in patients with HER2-positive MBC previously treated with trastuzumab and a taxane. Recently reported results from this study revealed that patients treated with T-DM1 had significantly longer median PFS and OS than those treated with lapatinib plus capecitabine.³³

Limitations of this study include its open-label design, with a primary end point of investigator-assessed PFS and a lower-than-expected proportion of patients treated with prior therapy in the adjuvant setting. The low percentage of patients treated with prior trastuzumab is especially notable; however, this may be explained by the high percentage of patients enrolled outside the United States and differences in regional practices. Another limitation is the immaturity of the OS data, with few deaths reported at the final analysis. More importantly, these data may be confounded by the large percentage of patients randomly assigned to the HT arm who crossed over to receive T-DM1 after PD (50%) and by the more than 50% of patients in both arms who received one or more subsequent anticancer treatments.

Given these limitations, these data should be considered hypothesis-generating, and they need to be validated by the results of MARIANNE, the ongoing phase III randomized study of T-DM1 with or without pertuzumab versus standard therapy (trastuzumab plus taxane) for the first-line treatment of HER2-positive MBC.^{34,35} In addition, the role of T-DM1 remains to be defined among other therapies for HER2-positive MBC.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Although all authors completed the disclosure declaration, the following author(s) and/or an author's immediate family member(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a "U" are those for which no compensation was received; those relationships marked with a "C" were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.

Employment or Leadership Position: Ellie Guardino, Genentech (C); Chunyan Song, Genentech (C); Barbara Tong, Genentech (C); Vivian Ng, Genentech (C); Yu-Way Chu, Genentech (C) **Consultant or Advisory Role:** None **Stock Ownership:** Ellie Guardino, Genentech; Chunyan Song, Genentech, Roche; Barbara Tong, Roche; Vivian Ng, Roche; Yu-Way Chu, Genentech **Honoraria:** Janice Lu, Genentech **Research Funding:** Sara A. Hurvitz, Genentech, Roche; Janice Lu, Genentech; Edith A. Perez, Genentech, GlaxoSmithKline **Expert Testimony:** None **Other Remuneration:** Sara A. Hurvitz, Roche

AUTHOR CONTRIBUTIONS

Conception and design: Luc Dirix, Ellie Guardino, Vivian Ng, Edith A. Perez

Provision of study materials or patients: Sara A. Hurvitz, Luc Dirix, Judit Kocsis, Edith A. Perez

Collection and assembly of data: Sara A. Hurvitz, Luc Dirix, Judit Kocsis, Giulia V. Bianchi, Janice Lu, Jeferson Vinholes, Ellie Guardino, Chunyan Song, Vivian Ng, Yu-Waye Chu, Edith A. Perez

Data analysis and interpretation: Luc Dirix, Ellie Guardino, Chunyan Song, Barbara Tong, Vivian Ng, Yu-Waye Chu, Edith A. Perez

Manuscript writing: All authors

Final approval of manuscript: All authors

REFERENCES

- Ross JS, Slodkowska EA, Symmans WF, et al: The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. *Oncologist* 14:320-368, 2009
- Dawood S, Broglio K, Buzdar AU, et al: Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review. *J Clin Oncol* 28:92-98, 2010
- Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* 235:177-182, 1987
- Seshadri R, Firgaira FA, Horsfall DJ, et al: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer: The South Australian Breast Cancer Study Group. *J Clin Oncol* 11:1936-1942, 1993
- Gabos Z, Sinha R, Hanson J, et al: Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastases after newly diagnosed breast cancer. *J Clin Oncol* 24:5658-5663, 2006
- Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. *J Clin Oncol* 14:737-744, 1996
- Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. *J Clin Oncol* 17:2639-2648, 1999
- Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. *J Clin Oncol* 20:719-726, 2002
- Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med* 344:783-792, 2001
- Marty M, Cognetti F, Maraninchi D, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. *J Clin Oncol* 23:4265-4274, 2005
- Perez EA, Suman VJ, Rowland KM, et al: Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. *Clin Breast Cancer* 6:425-432, 2005
- Lemieux J, Maunsell E, Provencher L: Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: A literature review. *Psychooncology* 17:317-328, 2008
- Lewis Phillips GD, Li G, Dugger DL, et al: Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. *Cancer Res* 68:9280-9290, 2008
- Junttila TT, Li G, Parsons K, et al: Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. *Breast Cancer Res Treat* 128:347-356, 2011
- Barok M, Tanner M, Köninki K, et al: Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. *Cancer Lett* 306:171-179, 2011
- Krop IE, Beeram M, Modi S, et al: Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. *J Clin Oncol* 28:2698-2704, 2010
- Krop IE, LoRusso P, Miller KD, et al: A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. *J Clin Oncol* 30:3234-3241, 2012
- Burris HA 3rd, Rugo HS, Vukelja SJ, et al: Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. *J Clin Oncol* 29:398-405, 2011
- Hurvitz SA, Dirix L, Kocsis J, et al: Trastuzumab emtansine (T-DM1) versus trastuzumab plus docetaxel in previously untreated HER2-positive metastatic breast cancer (MBC): Primary results of a randomized, multicenter, open-label phase II study (TDM4450g/BO21976). Presented at European Multidisciplinary Cancer Congress, Stockholm, Sweden, September 23-27, 2011 (abstr 5001)
- Perez EA, Dirix L, Kocsis J, et al: Efficacy and safety of trastuzumab-DM1 versus trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: Preliminary results of a randomized, multicenter, open-label phase 2 study. Presented at European Society of Medical Oncology, Milan, Italy, October 8-12, 2010 (abstr LBA3)
- Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* 92:205-216, 2000
- Brady MJ, Cella DF, Mo F, et al: Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. *J Clin Oncol* 15:974-986, 1997
- Eton DT, Cella D, Yost KJ, et al: A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. *J Clin Epidemiol* 57:898-910, 2004
- Bullock K, Blackwell K: Clinical efficacy of taxane-trastuzumab combination regimens for HER2-positive metastatic breast cancer. *Oncologist* 13:515-525, 2008
- Hamberg P, Bos MM, Braun HJ, et al: Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial. *Clin Breast Cancer* 11:103-113, 2011
- Cortes J, Roché H: Docetaxel combined with targeted therapies in metastatic breast cancer. *Cancer Treat Rev* 38:387-396, 2012
- Servitja S, Ramos M, Gil M, et al: Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2. *Anticancer Drugs* 23:239-246, 2012
- Suter TM, Procter M, van Veldhuisen DJ, et al: Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. *J Clin Oncol* 25:3859-3865, 2007
- Seidman AD, Berry D, Cirrincione C, et al: Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of Cancer and Leukemia Group B protocol 9840. *J Clin Oncol* 26:1642-1649, 2008
- Cella D, Wang M, Wagner L, et al: Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: Results from Eastern Cooperative Oncology Group Study 2100 (E2100). *Breast Cancer Res Treat* 130:855-861, 2011
- Corey-Lisle PK, Peck R, Mukhopadhyay P, et al: Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer. *Cancer* 118:461-468, 2012
- Sherrill B, Di Leo A, Amonkar MM, et al: Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. *Curr Med Res Opin* 26:767-775, 2010
- Verma S, Miles D, Gianni L, et al: Trastuzumab emtansine for HER2-positive advanced breast cancer. *N Engl J Med* 367:1783-1791, 2012
- ClinicalTrials.gov: A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab (Herceptin) Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE). <http://www.clinicaltrials.gov/ct2/show/NCT01120184>
- Ellis PA, Barrios CH, Im Y, et al: MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC). *J Clin Oncol* 29:7s, 2011 (suppl: abstr TPS102)

CORRECTIONS

Author Correction

The March 20, 2013, article by Hurvitz et al entitled “Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer” (J Clin Oncol 31:1157-1163, 2013), contained errors.

The percentage of patients with adverse events leading to treatment discontinuations in the control arm was given as 40.9%, whereas it should have been 34.8%. This requires correction in three instances as follows:

1) In the Abstract Results section, the third sentence should have read: “T-DM1 had a favorable safety profile versus HT, with fewer grade ≥ 3 adverse events (AEs; 46.4% v 90.9%), AEs leading to treatment discontinuations (7.2% v **34.8%**), and serious AEs (20.3% v 25.8%).”

2) In the Results section, under Safety, the second sentence of the first paragraph should have read: “Serious AEs (25.8% v

20.3%) and AEs leading to treatment discontinuation (**34.8%** v 7.2%) also occurred less frequently with T-DM1.”

3) In the Discussion section, the last sentence of the second paragraph should have read: “Furthermore, AEs leading to treatment discontinuation (of either drug) occurred in **34.8%** of patients in the HT group versus 7.2% in the T-DM1 group.”

In Table 1, a footnote should have been added indicating that the denominator in the control arm for the “number of distinct sites of involvement” is 69, rather than 70.

In Figure 1, the footnote (\ddagger) for efficacy analysis in the trastuzumab + docetaxel arm should have indicated that 70 patients were included in the analyses for progression-free survival and overall survival, while 69 patients were included in the objective response analysis.

The authors apologize for the mistakes.

DOI: 10.1200/JCO.2013.52.3639; published May 1, 2013

Journal Corrections

The January 1, 2005, article by Cristofanilli et al, entitled “Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes” (J Clin Oncol 23:41-48, 2005), contained an error.

The tenth author’s last name was inadvertently spelled as Bucholz and should have been spelled as Buchholz. *Journal of Clinical Oncology* apologizes for the mistake.

DOI: 10.1200/JCO.2013.52.3621; published May 1, 2013

The July 1, 2013, article by Hahn et al, entitled “Significant Improvement in Survival After Allogeneic Hematopoietic Cell Transplantation During a Period of Significantly Increased Use, Older Recipient Age, and Use of Unrelated Donors” (J Clin Oncol 31:2437-2449, 2013), contained errors.

In the Abstract, the second sentence under Results gave the increased use of peripheral blood as 6%, whereas it should have been 63%, as follows:

“From 1994 to 2005, use of both peripheral (7% to **63%**) and cord blood increased (2% to 10%), whereas use of marrow decreased (90% to 27%).”

In the same section, in the third sentence under Results, the increase in unrelated donors for alloHCT was omitted, whereas it should have been 165%, as follows:

“Despite a median age increase from 33 to 40 years and **165%** increase in unrelated donors for alloHCT, overall survival (OS) at day 100 significantly improved for patients with AML in first complete remission after myeloablative sibling alloHCT (85% to 94%; $P < .001$) and unrelated alloHCT (63% to 86%; $P < .001$). . .”

In Table 3, the Disease/Disease Status at HCT of the second row was given as “AML in CR with myeloablative conditioning intensity,” whereas it should have been “AML in CR2 with myeloablative conditioning intensity.”

The online version has been corrected in departure from the print. *Journal of Clinical Oncology* apologizes for the mistakes.

DOI: 10.1200/JCO.2013.52.3605; published May 1, 2013
